Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2017 Aug 22;18(8):1818.
doi: 10.3390/ijms18081818.

Peritoneal Mesothelioma with Residential Asbestos Exposure. Report of a Case with Long Survival (Seventeen Years) Analyzed by Cgh-Array

Affiliations
Case Reports

Peritoneal Mesothelioma with Residential Asbestos Exposure. Report of a Case with Long Survival (Seventeen Years) Analyzed by Cgh-Array

Gabriella Serio et al. Int J Mol Sci. .

Abstract

Malignant mesothelioma is a rare and aggressive tumor with limited therapeutic options. We report a case of a malignant peritoneal mesothelioma (MPM) epithelioid type, with environmental asbestos exposure, in a 36-year-old man, with a long survival (17 years). The patient received standard treatment which included cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).

Methods and results: Molecular analysis with comparative genomic hybridization (CGH)-array was performed on paraffin-embedded tumoral samples. Multiple chromosomal imbalances were detected. The gains were prevalent. Losses at 1q21, 2q11.1→q13, 8p23.1, 9p12→p11, 9q21.33→q33.1, 9q12→q21.33, and 17p12→p11.2 are observed. Chromosome band 3p21 (BAP1), 9p21 (CDKN2A) and 22q12 (NF2) are not affected. Conclusions: the defects observed in this case are uncommon in malignant peritoneal mesothelioma. Some chromosomal aberrations that appear to be random here, might actually be relevant events explaining the response to therapy, the long survival and, finally, may be considered useful prognostic factors in peritoneal malignant mesothelioma (PMM).

Keywords: asbestos; mesothelioma; molecular-array; peritoneum.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Malignant peritoneal mesothelioma: histology, immunohistochemical (IHC) and comparative genomic hybridization (CGH)-array results.

References

    1. Dogan A.U., Baris Y.I., Dogan M., Emri S., Steele I., Elmishad A.G., Carbone M. Genetic predisposition to fiber carcinogenesis causes a mesothelioma epidemic in Turkey. Cancer Res. 2006;66:5063–5082. doi: 10.1158/0008-5472.CAN-05-4642. - DOI - PubMed
    1. Reid A., de Klerk N.H., Magnani C., Ferrante D., Berry G., Musk A.W., Merler E. Mesothelioma risk after 40 years since first exposure to asbestos: A pooled analysis. Thorax. 2014;69:843–850. doi: 10.1136/thoraxjnl-2013-204161. - DOI - PubMed
    1. Yan T.D., Welch L., Black D., Sugarbaker P.H. A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann. Oncol. 2007;18:827–834. doi: 10.1093/annonc/mdl428. - DOI - PubMed
    1. Baumann F., Flores E., Napolitano A., Kanodia S., Taioli E., Pass H., Yang H., Carbone M. Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival. Carcinogenesis. 2015;36:76–81. doi: 10.1093/carcin/bgu227. - DOI - PMC - PubMed
    1. Thomas A., Chen Y., Yu T., Gill A., Prasad V. Distinctive clinical characteristics of malignant mesothelioma in young patients. Oncotarget. 2015;30:16766–16773. doi: 10.18632/oncotarget.4414. - DOI - PMC - PubMed

Publication types

LinkOut - more resources